H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)

H.C. Wainwright analyst Mitchel Kapoor reiterated a Buy rating and $45.00 price target on Neurogene (NASDAQ: NGNE).

The analyst commented: "TSHA jumped more than 45% (vs. XBI flat) on Breakthrough designation and a six-month interim Biologics License Application (BLA) plan, lifting its valuation to ~$1.2B, while NGNE barely moved and sits at just $257M market cap. Our diligence and physician feedback consistently point to durability, safety, and multidomain improvement as the decisive factors for approval and adoption—not simply speed. Neurogene’s FDA-cleared 12-month design risk-mitigates approvability; 2H25 data could drive a major re-rating in NGNE. In the wake of this update, we reiterate our Buy rating and 12-month price target of $45 per share."

For an analyst ratings summary and ratings history on Neurogene click here. For more ratings news on Neurogene click here.

Shares of Neurogene closed at $20.98 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
• Benchmark Reiterates Buy Rating on The Trade Desk (TTD)
• Liberty LiLAC (LILA) PT Lowered to $11 at Benchmark